The Biotechnology Innovation Organization is urging the US Federal Trade Commission to reconsider proposed revisions to merger guidelines, arguing that they would be “catastrophic” to the industry.
BIO objects to the directive that mergers should not eliminate a potential entrant in a concentrated market and the guideline specifying that when a merger is part of a series of multiple acquisitions, the FTC and Department of Justice may examine the whole series